Mometasone furoate in the treatment of allergic rhinitis: A complex therapeutic effect

The review examines the role of mometasone furoate (NSMF) intranasal spray (Nasonex) in the treatment of allergic rhinitis (AR). There is a wide prevalence of AR both among children and adults, its adverse effect on the quality of life of patients. It is emphasized that the main means of therapy for moderate and severe course in accordance with international and Russian recommendations for the diagnosis and treatment of AR are intranasal glucocorticosteroids (INGKS). The pharmacological features of the MF molecule that underlie its efficacy and safety, including the affinity, lipophilicity and viscosity of the drug, as well as low systemic bioavailability, are discussed in detail. The therapeutic effects of NSMF in the treatment of seasonal and perennial AR, its effect on nasal symptoms are discussed in detail. The beneficial effect of NSMF therapy on nasal congestion is emphasized separately. The beneficial effect of NSMF treatment on other clinical manifestations of AR, including ocular symptoms, effects on sleep, and olfactory function, has been noted. The safety issues of NSMF use are discussed in detail, including systemic effects, such as effects on adrenal function, eye, and growth retardation in children, and local adverse effects on the nasal mucosa; there is a high profile of local and systemic safety of long-term use of NSMF in the treatment of AR in both adults and children

CLINICAL EFFICIENCY OF ZINC PYRITHIONE TO TREAT ATOPIC DERMATITIS IN CHILDREN

Atopic dermatitis is one of the most widespread children’s diseases, it has a chronic recurrent clinical course, may be often complicated with the secondary infection. This necessitates the choice of a medication to impact all stages of the disease process with a high safety profile. This digest is devoted to activated zinc pyrithione. Overall, currently available data make it possible to state that this agent is one of the most effective and safest products to be used for a local therapy of atopic dermatitis in children. Key words: atopic dermatitis, activated zinc pyrithione, childre

CLINICAL EFFICIENCY OF ZINC PYRITHIONE TO TREAT ATOPIC DERMATITIS IN CHILDREN

Atopic dermatitis is one of the most widespread children’s diseases, it has a chronic recurrent clinical course, may be often complicated with the secondary infection. This necessitates the choice of a medication to impact all stages of the disease process with a high safety profile. This digest is devoted to activated zinc pyrithione. Overall, currently available data make it possible to state that this agent is one of the most effective and safest products to be used for a local therapy of atopic dermatitis in children. Key words: atopic dermatitis, activated zinc pyrithione, childre

КЛИНИЧЕСКАЯ ЭФФЕКТИВНОСТЬ И АНТИМИКРОБНАЯ АКТИВНОСТЬ ПИРИТИОНА ЦИНКА ПРИ АТОПИЧЕСКОМ ДЕРМАТИТЕ У ДЕТЕЙ

Atopic dermatitis is one of the most widespread children’s diseases, it has a chronic recurrent clinical course, may be often complicated with the secondary infection. This necessitates the choice of a medication to impact all stages of the disease process with a high safety profile. This digest is devoted to activated zinc pyrithione. Overall, currently available data make it possible to state that this agent is one of the most effective and safest products to be used for a local therapy of atopic dermatitis in children. Key words: atopic dermatitis, activated zinc pyrithione, childrenАтопический дерматит является одним из наиболее распространенных заболеваний в детской популяции, имеет хроническое рецидивирующее течение, часто осложняется вторичной инфекцией. Это диктует необходимость выбора препарата, воздействующего на все звенья патогенеза заболевания, и имеющего высокий профиль безопасности. Данная обзорная статья посвящена активированному пиритиону цинка (АПЦ). В целом, имеющиеся в настоящее время данные позволяют говорить об этом средстве, как об одном из наиболее эффективных и безопасных в ряду использующихся для местной терапии атопического дерматита у детей. Ключевые слова: атопический дерматит, активированный пиритион цинка, дети. (Педиатрическая фармакология. – 2009; 6(1):64-69)

Severe bronchial asthma patient care organization in various regions of the Russian Federation. From endotypes and phenotypes of bronchial asthma to personalized choice of therapy

© 2020 Consilium Medikum. All rights reserved. The meeting of the Expert board was held in Moscow on June 24, 2019, at which the following issues were considered: the applicability of a new terminology characterizing asthma endotypes and phenotypes in real clinical practice, the effect of phenotypes and biomarkers in patients with bronchial asthma on the choice of biological drug, as well as the optimal clinical profiles of patients for whom dupilumab is most effective, taking into account the data of the III phase clinical trials, regional features of medical care and changes in updated international clinical guidelines for the diagnosis and treatment of asthma. The Expert board included members of leading Russian scientific and educational medical institutions: S.N. Avdeev, corresponding member of the Russian Academy of Sciences, prof., MD; O.A. Volkova, Ph.D.; I.V. Demko, prof., MD; G.L. Ignatova, prof., MD; I.V. Leshchenko, prof., MD; Kanukova N.A.; Kudelya L.M., prof., MD; V.A. Nevzorova, prof., MD; N.G. Nedashkovskaya; O.P. Ukhanova, prof., MD; L.V. Shulzhenko, prof., MD; R.S. Fassakhov, prof., MD

Аnaphylactic shock. Сlinical guidelines

Anaphylactic shock is a severe life-threatening condition caused by medicines, food, hymenoptera, animal poisons, etc. Therefore, anaphylactic shock (anaphylaxis) can develop both in medical institution and outside it, and physicians of any specialties should be ready to treat this condition. In this regard, clinical guidelines for anaphylactic shock have been developed. These recommendations were approved by the Russian Association of Allergy and Clinical Immunology (Protocol No. 743/12 dated December 30, 2020) and the Federation of Anesthesiologists and Resuscitators (Protocol No. 1 dated January 13, 2021), approved at a meeting of the Scientific and Practical Council of the Ministry of Health of the Russian Federation (Protocol No. 743/12 dated December 10, 2020). Guidelines covered a number of nosologies corresponding to codes of the International Statistical Classification of Diseases and Related Health Problems: T 78.0; T 78.2; T 80.5; T 88.6. The clinical guidelines systematize modern data on etiology, epidemiology, classification, clinical picture, diagnosis, treatment, and prevention of anaphylactic shock. In addition, an algorithm for managing a patient with anaphylactic shock has been developed. Clinical guidelines for anaphylactic shock are intended for practitioners of all specialties, students, and teachers of medical universities, residents, and graduate students

Practical recommendations for choosing an immunobiological preparation for the treatment of severe bronchial asthma of T2-endotype

© 2020 Medical Education. All rights reserved. Biological therapy of bronchial asthma (BA) is a modern method of treating severe forms of the disease, that are uncontrolled by traditional pharmacotherapeutic approaches. Currently, 5 monoclonal antibody (AT) preparations are registered in the world for the treatment of severe bronchial asthma (SBA) of the T2 endotype (T2-SBA) - antibodies, binding to immunoglobulin (Ig) E (anti-IgE - omalizumab), interleukin antagonists (IL)-5 (anti-IL-5 - mepolizumab, resizumab) and its receptor (anti-IL-5Rα - benralizumab), as well as antibodies, that selectively bind to the IL-4 and -13 receptor (anti-IL-4 /13Rα - dupilumab). The article presents data on the effectiveness of these drugs in relation to the key characteristics of SBA, formulates clinical and laboratory criteria, the study of which in real practice can potentially predict the likelihood of a clinical response to a particular type of biological therapy. An algorithm is proposed for choosing a targeted therapy strategy for patients with SBA, clinically associated with allergies, for patients with severe non-allergic eosinophilic BA and for patients with eosinophilic BA of a combined phenotype

Toward personalization of asthma treatment according to trigger factors

Asthma is a severe and chronic disabling disease affecting more than 300 million people worldwide. Although in the past few drugs for the treatment of asthma were available, new treatment options are currently emerging, which appear to be highly effective in certain subgroups of patients. Accordingly, there is a need for biomarkers that allow selection of patients for refined and personalized treatment strategies. Recently, serological chip tests based on microarrayed allergen molecules and peptides derived from the most common rhinovirus strains have been developed, which may discriminate 2 of the most common forms of asthma, that is, allergen- and virus-triggered asthma. In this perspective, we argue that classification of patients with asthma according to these common trigger factors may open new possibilities for personalized management of asthma. © 2020 The Author

Toward personalization of asthma treatment according to trigger factors

© 2020 The Authors Asthma is a severe and chronic disabling disease affecting more than 300 million people worldwide. Although in the past few drugs for the treatment of asthma were available, new treatment options are currently emerging, which appear to be highly effective in certain subgroups of patients. Accordingly, there is a need for biomarkers that allow selection of patients for refined and personalized treatment strategies. Recently, serological chip tests based on microarrayed allergen molecules and peptides derived from the most common rhinovirus strains have been developed, which may discriminate 2 of the most common forms of asthma, that is, allergen- and virus-triggered asthma. In this perspective, we argue that classification of patients with asthma according to these common trigger factors may open new possibilities for personalized management of asthma